Skip to main content
Top
Published in: PharmacoEconomics 1/2011

01-01-2011 | Original Research Article

Calibrating Models in Economic Evaluation

A Comparison of Alternative Measures of Goodness of Fit, Parameter Search Strategies and Convergence Criteria

Authors: Dr Jonathan Karnon, Tazio Vanni

Published in: PharmacoEconomics | Issue 1/2011

Login to get access

Abstract

Background: The importance of assessing the accuracy of health economic decision models is widely recognized. Many applied decision models (implicitly) assume that the process of identifying relevant values for a model’s input parameters is sufficient to prove the model’s accuracy. The selection of infeasible combinations of input parameter values is most likely in the context of probabilistic sensitivity analysis (PSA), where parameter values are drawn from independently specified probability distributions for each model parameter. Model calibration involves the identification of input parameter values that produce model output parameters that best predict observed data.
Methods: An empirical comparison of three key calibration issues is presented: the applied measure of goodness of fit (GOF); the search strategy for selecting sets of input parameter values; and the convergence criteria for determining acceptable GOF. The comparisons are presented in the context of probabilistic calibration, a widely applicable approach to calibration that can be easily integrated with PSA. The appendix provides a user’s guide to probabilistic calibration, with the reader invited to download the Microsoft® Excel-based model reported in this article.
Results: The calibrated models consistently provided higher mean estimates of the models’ output parameter, illustrating the potential gain in accuracy derived from calibrating decision models. Model uncertainty was also reduced. The chi-squared GOF measure differentiated between the accuracy of different parameter sets to a far greater degree than the likelihood GOF measure. The guided search strategy produced higher mean estimates of the models’ output parameter, as well as a narrower range of predicted output values, which may reflect greater precision in the identification of candidate parameter sets or more limited coverage of the parameter space. The broader convergence threshold resulted in lower mean estimates of the models’ output, and slightly wider ranges, which were closer to the outputs associated with the non-calibrated approach.
Conclusions: Probabilistic calibration provides a broadly applicable method that will improve the relevance of health economic decision models, and simultaneously reduce model uncertainty. The analyses reported in this paper inform the more efficient and accurate application of calibration methods for health economic decision models.
Appendix
Available only for authorised users
Literature
3.
go back to reference Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): 1–172PubMed Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): 1–172PubMed
4.
go back to reference Weinstein MC. Recent developments in decision-analytic modeling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 043–53CrossRef Weinstein MC. Recent developments in decision-analytic modeling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 043–53CrossRef
5.
go back to reference Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics 2011; 29 (1): 35–49CrossRefPubMed Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics 2011; 29 (1): 35–49CrossRefPubMed
6.
go back to reference Karnon J, Delea TE, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 2008; 9: 171–83CrossRefPubMed Karnon J, Delea TE, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 2008; 9: 171–83CrossRefPubMed
7.
go back to reference Karnon J, McIntosh A, Dean J, et al. A prospective hazard and improvement analytic approach to predicting the effectiveness of medication error interventions. Saf Sci 2007; 45: 523–39CrossRef Karnon J, McIntosh A, Dean J, et al. A prospective hazard and improvement analytic approach to predicting the effectiveness of medication error interventions. Saf Sci 2007; 45: 523–39CrossRef
8.
go back to reference Carlton J, Karnon J, Czoski-Murray C, et al. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4–5 years: a systematic review and economic evaluation. Health Technol Assess 2008; 12 (25): iii, xi–194 Carlton J, Karnon J, Czoski-Murray C, et al. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4–5 years: a systematic review and economic evaluation. Health Technol Assess 2008; 12 (25): iii, xi–194
9.
go back to reference Karnon J, Jones R, Czoski-Murray C, et al. Cost-utility analysis of screening high risk groups for anal cancer. J Public Health 2008 Sep; 30: 293–304CrossRef Karnon J, Jones R, Czoski-Murray C, et al. Cost-utility analysis of screening high risk groups for anal cancer. J Public Health 2008 Sep; 30: 293–304CrossRef
10.
go back to reference Karnon J, Campbell F, Czoski-Murray C. Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). J Eval Clin Pract 2009; 15 (2): 299–306CrossRefPubMed Karnon J, Campbell F, Czoski-Murray C. Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). J Eval Clin Pract 2009; 15 (2): 299–306CrossRefPubMed
11.
go back to reference Karnon J, Czoski Murray C, Smith KJ, et al. A hybrid cohort individual sampling natural history model of agerelatedmacular degeneration: assessing the cost-effectiveness of screening using probabilistic calibration. Med Decis Making 2009; 29: 304–16CrossRefPubMed Karnon J, Czoski Murray C, Smith KJ, et al. A hybrid cohort individual sampling natural history model of agerelatedmacular degeneration: assessing the cost-effectiveness of screening using probabilistic calibration. Med Decis Making 2009; 29: 304–16CrossRefPubMed
12.
go back to reference Karnon J. Cost considerations and cost effectiveness of aromatase inhibitors in breast cancer. Pharmacoeconomics 2006; 24 (3): 215–32CrossRefPubMed Karnon J. Cost considerations and cost effectiveness of aromatase inhibitors in breast cancer. Pharmacoeconomics 2006; 24 (3): 215–32CrossRefPubMed
13.
go back to reference Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717CrossRef Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717CrossRef
14.
go back to reference The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57CrossRef The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57CrossRef
15.
go back to reference Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365 (9453): 60–2CrossRefPubMed Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365 (9453): 60–2CrossRefPubMed
16.
go back to reference Jit M, Gay N, Soldan K, et al. Estimating progression rates for human papillomavirus infection from epidemiological data. Med Decis Making 2010; 30: 84–98CrossRefPubMed Jit M, Gay N, Soldan K, et al. Estimating progression rates for human papillomavirus infection from epidemiological data. Med Decis Making 2010; 30: 84–98CrossRefPubMed
18.
go back to reference Kim JJ, Kuntz KM, Stout NK, et al. Multi-parameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137–50CrossRefPubMed Kim JJ, Kuntz KM, Stout NK, et al. Multi-parameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137–50CrossRefPubMed
19.
go back to reference Ades AE, Welton NJ, Caldwell D, et al. Multi-parameter evidence synthesis in epidemiology and medical decision making. J Health Serv Res Policy 2008; 13 Suppl. 3: 12–22CrossRefPubMed Ades AE, Welton NJ, Caldwell D, et al. Multi-parameter evidence synthesis in epidemiology and medical decision making. J Health Serv Res Policy 2008; 13 Suppl. 3: 12–22CrossRefPubMed
Metadata
Title
Calibrating Models in Economic Evaluation
A Comparison of Alternative Measures of Goodness of Fit, Parameter Search Strategies and Convergence Criteria
Authors
Dr Jonathan Karnon
Tazio Vanni
Publication date
01-01-2011
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 1/2011
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11584610-000000000-00000

Other articles of this Issue 1/2011

PharmacoEconomics 1/2011 Go to the issue

Correspondence

The Authors’ Reply